Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233

Steven N. Gurley, Ammaar Abidi, Patrick Allison, Peihong Guan, Christopher Duntsch, Jon H. Robertson, Stanley D. Kosanke, Stephen T. Keir, Darell D. Bigner, Andrea J. Elberger, Bob Moore

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Glioblastoma multiforme (GBM) is the most common and devastating form of primary central nervous system malignancy. The prognosis for patients diagnosed with GBM is poor, having a median survival rate of 12-15 months. Despite modern advances in the development of antineoplastic agents, the efficacy of newer anti-cancer agents in the treatment of GBM is yet to be determined. Thus, there remains a significant unmet need for new therapeutic strategies against GBM. A promising chemotherapeutic intervention has emerged from studies of cannabinoid receptor agonists wherein tetrahydrocannabinol has been the most extensively studied. The novel cannabinoid ligand KM-233 was developed as a lead platform for future optimization of biopharmaceutical properties of classical based cannabinoid ligands. Treatment of U87MG human GBM cells with KM-233 caused a time dependent change in the phosphorylation profiles of MEK, ERK1/2, Akt, BAD, STAT3, and p70S6K. Almost complete mitochondrial depolarization was observed 6 h post-treatment followed by a rapid increase in cleaved caspase 3 and significant cytoskeletal contractions. Treatment with KM-233 also resulted in a redistribution of the Golgi-endoplasmic reticulum structures. Dose escalation studies in the orthotopic model using U87MG cells revealed an 80 % reduction in tumor size after 12 mg/kg daily dosing for 20 days. The evaluation of KM-233 against primary tumor tissue in the side flank model revealed a significant decrease in the rate of tumor growth. These findings indicate that structural refinement of KM-233 to improve its biopharmaceutical properties may lead to a novel and efficacious treatment for GBM.

Original languageEnglish (US)
Pages (from-to)163-177
Number of pages15
JournalJournal of Neuro-Oncology
Volume110
Issue number2
DOIs
StatePublished - Nov 1 2012

Fingerprint

Cannabinoids
Glioblastoma
Glioma
Ligands
Neoplasms
Therapeutics
Cannabinoid Receptor Agonists
70-kDa Ribosomal Protein S6 Kinases
Dronabinol
Mitogen-Activated Protein Kinase Kinases
Caspase 3
Endoplasmic Reticulum
Antineoplastic Agents
KM-233
Survival Rate
Central Nervous System
Phosphorylation
Growth

All Science Journal Classification (ASJC) codes

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233. / Gurley, Steven N.; Abidi, Ammaar; Allison, Patrick; Guan, Peihong; Duntsch, Christopher; Robertson, Jon H.; Kosanke, Stanley D.; Keir, Stephen T.; Bigner, Darell D.; Elberger, Andrea J.; Moore, Bob.

In: Journal of Neuro-Oncology, Vol. 110, No. 2, 01.11.2012, p. 163-177.

Research output: Contribution to journalArticle

Gurley, SN, Abidi, A, Allison, P, Guan, P, Duntsch, C, Robertson, JH, Kosanke, SD, Keir, ST, Bigner, DD, Elberger, AJ & Moore, B 2012, 'Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233', Journal of Neuro-Oncology, vol. 110, no. 2, pp. 163-177. https://doi.org/10.1007/s11060-012-0958-5
Gurley, Steven N. ; Abidi, Ammaar ; Allison, Patrick ; Guan, Peihong ; Duntsch, Christopher ; Robertson, Jon H. ; Kosanke, Stanley D. ; Keir, Stephen T. ; Bigner, Darell D. ; Elberger, Andrea J. ; Moore, Bob. / Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233. In: Journal of Neuro-Oncology. 2012 ; Vol. 110, No. 2. pp. 163-177.
@article{d7edfdffa0754203bd4b2264116ebc88,
title = "Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233",
abstract = "Glioblastoma multiforme (GBM) is the most common and devastating form of primary central nervous system malignancy. The prognosis for patients diagnosed with GBM is poor, having a median survival rate of 12-15 months. Despite modern advances in the development of antineoplastic agents, the efficacy of newer anti-cancer agents in the treatment of GBM is yet to be determined. Thus, there remains a significant unmet need for new therapeutic strategies against GBM. A promising chemotherapeutic intervention has emerged from studies of cannabinoid receptor agonists wherein tetrahydrocannabinol has been the most extensively studied. The novel cannabinoid ligand KM-233 was developed as a lead platform for future optimization of biopharmaceutical properties of classical based cannabinoid ligands. Treatment of U87MG human GBM cells with KM-233 caused a time dependent change in the phosphorylation profiles of MEK, ERK1/2, Akt, BAD, STAT3, and p70S6K. Almost complete mitochondrial depolarization was observed 6 h post-treatment followed by a rapid increase in cleaved caspase 3 and significant cytoskeletal contractions. Treatment with KM-233 also resulted in a redistribution of the Golgi-endoplasmic reticulum structures. Dose escalation studies in the orthotopic model using U87MG cells revealed an 80 {\%} reduction in tumor size after 12 mg/kg daily dosing for 20 days. The evaluation of KM-233 against primary tumor tissue in the side flank model revealed a significant decrease in the rate of tumor growth. These findings indicate that structural refinement of KM-233 to improve its biopharmaceutical properties may lead to a novel and efficacious treatment for GBM.",
author = "Gurley, {Steven N.} and Ammaar Abidi and Patrick Allison and Peihong Guan and Christopher Duntsch and Robertson, {Jon H.} and Kosanke, {Stanley D.} and Keir, {Stephen T.} and Bigner, {Darell D.} and Elberger, {Andrea J.} and Bob Moore",
year = "2012",
month = "11",
day = "1",
doi = "10.1007/s11060-012-0958-5",
language = "English (US)",
volume = "110",
pages = "163--177",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233

AU - Gurley, Steven N.

AU - Abidi, Ammaar

AU - Allison, Patrick

AU - Guan, Peihong

AU - Duntsch, Christopher

AU - Robertson, Jon H.

AU - Kosanke, Stanley D.

AU - Keir, Stephen T.

AU - Bigner, Darell D.

AU - Elberger, Andrea J.

AU - Moore, Bob

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Glioblastoma multiforme (GBM) is the most common and devastating form of primary central nervous system malignancy. The prognosis for patients diagnosed with GBM is poor, having a median survival rate of 12-15 months. Despite modern advances in the development of antineoplastic agents, the efficacy of newer anti-cancer agents in the treatment of GBM is yet to be determined. Thus, there remains a significant unmet need for new therapeutic strategies against GBM. A promising chemotherapeutic intervention has emerged from studies of cannabinoid receptor agonists wherein tetrahydrocannabinol has been the most extensively studied. The novel cannabinoid ligand KM-233 was developed as a lead platform for future optimization of biopharmaceutical properties of classical based cannabinoid ligands. Treatment of U87MG human GBM cells with KM-233 caused a time dependent change in the phosphorylation profiles of MEK, ERK1/2, Akt, BAD, STAT3, and p70S6K. Almost complete mitochondrial depolarization was observed 6 h post-treatment followed by a rapid increase in cleaved caspase 3 and significant cytoskeletal contractions. Treatment with KM-233 also resulted in a redistribution of the Golgi-endoplasmic reticulum structures. Dose escalation studies in the orthotopic model using U87MG cells revealed an 80 % reduction in tumor size after 12 mg/kg daily dosing for 20 days. The evaluation of KM-233 against primary tumor tissue in the side flank model revealed a significant decrease in the rate of tumor growth. These findings indicate that structural refinement of KM-233 to improve its biopharmaceutical properties may lead to a novel and efficacious treatment for GBM.

AB - Glioblastoma multiforme (GBM) is the most common and devastating form of primary central nervous system malignancy. The prognosis for patients diagnosed with GBM is poor, having a median survival rate of 12-15 months. Despite modern advances in the development of antineoplastic agents, the efficacy of newer anti-cancer agents in the treatment of GBM is yet to be determined. Thus, there remains a significant unmet need for new therapeutic strategies against GBM. A promising chemotherapeutic intervention has emerged from studies of cannabinoid receptor agonists wherein tetrahydrocannabinol has been the most extensively studied. The novel cannabinoid ligand KM-233 was developed as a lead platform for future optimization of biopharmaceutical properties of classical based cannabinoid ligands. Treatment of U87MG human GBM cells with KM-233 caused a time dependent change in the phosphorylation profiles of MEK, ERK1/2, Akt, BAD, STAT3, and p70S6K. Almost complete mitochondrial depolarization was observed 6 h post-treatment followed by a rapid increase in cleaved caspase 3 and significant cytoskeletal contractions. Treatment with KM-233 also resulted in a redistribution of the Golgi-endoplasmic reticulum structures. Dose escalation studies in the orthotopic model using U87MG cells revealed an 80 % reduction in tumor size after 12 mg/kg daily dosing for 20 days. The evaluation of KM-233 against primary tumor tissue in the side flank model revealed a significant decrease in the rate of tumor growth. These findings indicate that structural refinement of KM-233 to improve its biopharmaceutical properties may lead to a novel and efficacious treatment for GBM.

UR - http://www.scopus.com/inward/record.url?scp=84867842472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867842472&partnerID=8YFLogxK

U2 - 10.1007/s11060-012-0958-5

DO - 10.1007/s11060-012-0958-5

M3 - Article

VL - 110

SP - 163

EP - 177

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -